• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

前列腺特异性抗原密度和 Gleason 评分可预测临床局限性前列腺癌患者的不良病理特征。

Prostate-Specific Antigen Density and Gleason Score Predict Adverse Pathologic Features in Patients with Clinically Localized Prostate Cancer.

作者信息

Nowroozi Mohammad Reza, Momeni Seyed Ali, Ohadian Moghadam Solmaz, Ayati Elnaz, Mortazavi Afshin, Arfae Simin, Jamshidian Hassan, Taherimahmoudi Mohsen, Ayati Mohsen

机构信息

Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.

出版信息

Nephrourol Mon. 2016 Aug 15;8(6):e39984. doi: 10.5812/numonthly.39984. eCollection 2016 Nov.

DOI:10.5812/numonthly.39984
PMID:27896239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5120234/
Abstract

BACKGROUND

According to recent studies, prostate cancer is the second most common cancer among Iranian men. Radical prostatectomy has been considered the gold standard treatment in patients with clinically localized prostate cancer. Gleason score, PSA density, and PSA velocity are some of the parameters used to predict adverse pathologic features.

OBJECTIVES

The aim of this study was to evaluate the prognostic value of PSA density and Gleason score in predicting adverse pathologic features in patients with localized prostate cancer who undergo radical prostatectomy.

METHODS

We conducted a cross-sectional study of 105 patients with localized prostate cancer who underwent radical prostatectomy between 2006 and 2013. We recorded Gleason scores and PSA levels, in addition to the results of pathological evaluations after radical prostatectomy, including prostate volume, stage, LNI (lymph node involvement), SVI (seminal vesicle invasion), and extraprostatic extension (EPE). Data were analyzed using SPSS version 21.

RESULTS

Mean PSA density was 0.27 (0.17 SD). The frequencies of EPE, SVI, and LNI were 21.9, 16.2, and 2.9, respectively. The Mann-Whitney U-test demonstrated a significant correlation between PSA density and adverse pathologic features (EPE, SVI, and LNI).

CONCLUSIONS

PSA, PSA density, and Gleason score should be considered together in order to more accurately predict the adverse pathologic features of prostate cancer.

摘要

背景

根据最近的研究，前列腺癌是伊朗男性中第二常见的癌症。根治性前列腺切除术一直被认为是临床局限性前列腺癌患者的金标准治疗方法。 Gleason评分、PSA密度和PSA速度是用于预测不良病理特征的一些参数。

目的

本研究的目的是评估PSA密度和Gleason评分在预测接受根治性前列腺切除术的局限性前列腺癌患者不良病理特征方面的预后价值。

方法

我们对2006年至2013年间接受根治性前列腺切除术的105例局限性前列腺癌患者进行了横断面研究。我们记录了Gleason评分和PSA水平，以及根治性前列腺切除术后的病理评估结果，包括前列腺体积、分期、LNI（淋巴结受累）、SVI（精囊侵犯）和前列腺外扩展（EPE）。使用SPSS 21版对数据进行分析。

结果

平均PSA密度为0.27（标准差0.17）。EPE、SVI和LNI的发生率分别为21.9%、16.2%和2.9%。Mann-Whitney U检验显示PSA密度与不良病理特征（EPE、SVI和LNI）之间存在显著相关性。

结论

应综合考虑PSA、PSA密度和Gleason评分，以便更准确地预测前列腺癌的不良病理特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ec/5120234/5b15c423d008/num-08-06-39984-i001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ec/5120234/5b15c423d008/num-08-06-39984-i001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ec/5120234/5b15c423d008/num-08-06-39984-i001.jpg

相似文献

1
Prostate-Specific Antigen Density and Gleason Score Predict Adverse Pathologic Features in Patients with Clinically Localized Prostate Cancer.前列腺特异性抗原密度和 Gleason 评分可预测临床局限性前列腺癌患者的不良病理特征。
Nephrourol Mon. 2016 Aug 15;8(6):e39984. doi: 10.5812/numonthly.39984. eCollection 2016 Nov.
2
PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer.在临床局限性前列腺癌患者中，前列腺特异性抗原密度（PSA density）在预测不良病理特征方面优于前列腺特异性抗原（PSA）和 Gleason 评分。
Can Urol Assoc J. 2012 Feb;6(1):46-50. doi: 10.5489/cuaj.11079.
3
Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.通过前列腺特异性抗原密度、直肠内磁共振成像及活检Gleason评分预测临床局限性前列腺癌的前列腺外癌
Prostate. 2003 Jun 15;56(1):23-9. doi: 10.1002/pros.10239.
4
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.前列腺特异性抗原提高了临床分期和活检 Gleason 评分在新千年预测根治性前列腺切除术后病理分期的能力。
Eur Urol. 2007 Oct;52(4):1067-74. doi: 10.1016/j.eururo.2007.03.018. Epub 2007 Mar 20.
5
Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis.基于穿刺活检结果预测前列腺癌的前列腺外侵犯：神经周围浸润在多变量分析中无显著意义。
Am J Surg Pathol. 1997 Dec;21(12):1496-500. doi: 10.1097/00000478-199712000-00013.
6
Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients.北美高危前列腺癌患者根治性前列腺切除术后的当代病理分期分布。
Clin Genitourin Cancer. 2022 Oct;20(5):e380-e389. doi: 10.1016/j.clgc.2022.04.005. Epub 2022 Apr 21.
7
Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.前列腺癌核分级与根治性前列腺切除术后前列腺特异性抗原复发之间无相关性。
J Urol. 2001 Dec;166(6):2193-7.
8
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.根治性前列腺切除术后前列腺特异性抗原持续存在对预测淋巴结阳性前列腺癌患者临床进展和癌症特异性死亡率的作用。
Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.
9
Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.机器人辅助根治性前列腺切除术后患者前列腺特异性抗原持续升高的预测因素及肿瘤学结局
J Robot Surg. 2017 Mar;11(1):37-45. doi: 10.1007/s11701-016-0606-8. Epub 2016 May 31.
10
The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.在多变量分析中纳入直肠内线圈磁共振成像以预测临床未怀疑的前列腺外癌的影响。
Cancer. 1995 May 1;75(9):2368-72. doi: 10.1002/1097-0142(19950501)75:9<2368::aid-cncr2820750929>3.0.co;2-#.

引用本文的文献

1
phi and phiD predict adverse pathological features after radical prostatectomy for prostate cancer in Chinese population.phi 和 phiD 可预测中国人群前列腺癌根治术后的不良病理特征。
Cancer Med. 2024 Aug;13(15):e70085. doi: 10.1002/cam4.70085.
2
Human microbiome and prostate cancer development: current insights into the prevention and treatment.人类微生物组与前列腺癌的发生发展：预防和治疗的最新研究进展。
Front Med. 2021 Feb;15(1):11-32. doi: 10.1007/s11684-019-0731-7. Epub 2020 Jun 30.
3
Overexpression of NCAPH is upregulated and predicts a poor prognosis in prostate cancer.

本文引用的文献

1
PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer.在临床局限性前列腺癌患者中，前列腺特异性抗原密度（PSA density）在预测不良病理特征方面优于前列腺特异性抗原（PSA）和 Gleason 评分。
Can Urol Assoc J. 2012 Feb;6(1):46-50. doi: 10.5489/cuaj.11079.
2
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.癌症统计数据，2011 年：消除社会经济和种族差异对癌症过早死亡的影响。
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
3
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
NCAPH的过表达上调，并预示前列腺癌预后不良。
Oncol Lett. 2019 Jun;17(6):5768-5776. doi: 10.3892/ol.2019.10260. Epub 2019 Apr 17.
4
Eukaryotic Elongation Factor 2 (eEF2) is a Potential Biomarker of Prostate Cancer.真核延伸因子2（eEF2）是前列腺癌的潜在生物标志物。
Pathol Oncol Res. 2018 Oct;24(4):885-890. doi: 10.1007/s12253-017-0302-7. Epub 2017 Sep 14.
EAU 前列腺癌指南。第 1 部分：局限性疾病的筛查、诊断和治疗。
Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.
4
Toward prostate cancer early detection in Iran.迈向伊朗前列腺癌的早期检测。
Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):413-8.
5
International epidemiology of prostate cancer: geographical distribution and secular trends.前列腺癌的国际流行病学：地理分布与长期趋势。
Mol Nutr Food Res. 2009 Feb;53(2):171-84. doi: 10.1002/mnfr.200700511.
6
Integrative biology of prostate cancer progression.前列腺癌进展的整合生物学
Annu Rev Pathol. 2006;1:243-71. doi: 10.1146/annurev.pathol.1.110304.100047.
7
Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.前列腺特异性抗原密度可预测不良病理情况及生化复发风险增加。
Urology. 2007 Jun;69(6):1121-7. doi: 10.1016/j.urology.2007.01.087.
8
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.基于2000年至2005年的病例，更新了列线图，以根据前列腺特异性抗原水平、临床分期和活检Gleason评分（Partin表）预测前列腺癌的病理分期。
Urology. 2007 Jun;69(6):1095-101. doi: 10.1016/j.urology.2007.03.042.
9
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.前列腺特异性抗原密度与前列腺癌侵袭性特征相关。
J Urol. 2007 Feb;177(2):505-9. doi: 10.1016/j.juro.2006.09.039.
10
Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.前列腺特异性抗原与前列腺特异性抗原密度作为前列腺癌肿瘤体积、切缘状态、病理分期及生化复发的预测指标
Urology. 2005 Dec;66(6):1229-33. doi: 10.1016/j.urology.2005.06.106.